GleamWall
中文EN

SNDX Syndax Pharmaceuticals Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1395937 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY159.7%
TTM net income YoY32.8%
TTM EPS YoY34.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-61.7%
Net margin-72.3%
FCF margin—
EBITDA margin-55.5%

Returns

ROE-426.4%
ROA-33.7%
ROIC (approx.)—
Asset turnover0.47x

Leverage & solvency

Liabilities / assets102.5%
Debt / equity—
Current ratio4.69x
Interest coverage-44,660.00x

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$172.35M$23.68M
R&D expense$258.78M$241.65M
SG&A expense$179.68M$120.88M
Operating income-$273.08M-$339.67M
Interest expense$6,000-$1,000
Income tax$433,000—
Net income-$285.42M-$318.76M
EBITDA-$267.08M-$331.67M
EPS (basic)-3.29-3.72
EPS (diluted)-3.29-3.72
Weighted avg. shares (diluted)86.63M85.62M
Balance sheet
Cash & equivalents$134.93M$154.08M
Short-term investments$259.14M$418.80M
Receivables$38.00M$7.60M
Inventory$32.75M$366,000
Current assets$528.08M$603.06M
PP&E, net$181,000$0
Total assets$529.71M$724.82M
Current liabilities$120.12M$103.55M
Short-term debt$343.91M$343.68M
Total liabilities$465.08M$436.69M
Shareholders' equity$64.63M$288.12M
Shares outstanding87.41M85.69M
Cash flow statement
Operating cash flow-$322.98M-$274.90M
Capital expenditure$187,000$0
Free cash flow-$323.17M-$274.90M
Investing cash flow$290.04M-$219.78M
Financing cash flow$13.68M$353.37M
Depreciation & amortization$6.00M$8.00M
Stock-based compensation$47.50M$43.03M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.